









## Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on September 2024

### Classification of products:

Status	Description
 <b>GREEN</b>	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 <b>AMB 1</b>	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 <b>AMB 2</b>	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 <b>AMB SCP</b>	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 <b>RED</b>	Red-Hospital initiation and continuation only
 <b>GREY</b>	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 <b>PURPLE</b>	To be supplied from the appropriate commissioned provider.
 <b>NR</b>	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>1) Requests deferred from previous meetings</b>				
Nil this month				
<b>2) New Requests</b>				
Dalbavancin	<b>RED</b>			For OPAT use only
Chloral hydrate liquid	<b>RED</b>			Features in specific Guidelines of both HUTH and NLaG
<b>3) New formulations &amp; extensions to use</b>				

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Sitagliptin	GREEN			Changed to first line choice with alogliptin and linagliptin to second line
4) Products considered by NICE				
<a href="#">TA985: Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma</a>	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<a href="#">TA986: Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over</a>	RED			The formulary will reflect the TAG – ICS is the responsible commissioner.
<a href="#">TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis</a>	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<a href="#">TA989: Etranacogene dezaparovec for treating moderately severe or severe haemophilia B</a>	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<a href="#">TA990: Tenecteplase for treating acute ischaemic stroke</a>	RED			The formulary will reflect the TAG – ICS is the responsible commissioner.
5) Appeals against earlier decisions by the APC				
Nil this month				
6) Miscellaneous formulary decisions by the APC				
Nil this month				

The following guidelines and pathways were presented to and approved at the September 2024 meeting of the APC:

- HNY ICS generic eye preparations

The following Drug information leaflets were presented to and approved at the September 2024 meeting of the APC:

- Nil this month

The following shared care guidelines were presented to and approved at the September 2024 meeting of the APC:

- Valproate SCF (ICS)
- Atomoxetine SCF (HFT)
- Methylphenidate SCF (HFT)
- Dexamphetamine SCF (HFT)

DECISION SUMMARY

Other documents presented to and approved at the September 2024 meeting of the APC:

- Nil this month